Avalglucosidase Alfa Pregnancy Study
Study Overview
This is a worldwide, descriptive safety study collecting data on women and their offspring exposed to avalglucosidase alfa during pregnancy and/or lactation, to assess the risks of avalglucsodiase alfa on pregnancy and maternal complications and adverse effects in the developing fetus, neonate, and infant.
- Outcomes in exposed infants, including growth and development, will be assessed through at least the first year of life.
- Data will be collected for approximately 10 years.
Study details
Study Design Time Perspective: Retrospective and Prospective
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Pompe Disease, Pregnancy
-
Gender: Female
Inclusion Criteria:
- Women and their offspring exposed to avalglucosidase alfa during pregnancy and/or lactation for whom an Individual Case Safety Report (ICSR) has been submitted to the Sanofi Global Pharmacovigilance (PV) department, and/or,
- Women exposed to avalglucosidase alfa during pregnancy and/or lactation who have provided informed consent to enroll in the Pompe Pregnancy Sub-registry.
Exclusion Criteria:
There are no exclusion criteria in this study.
The above information is not intended to contain all considerations relevant to a potential
participation in a clinical trial.
Find a Study Location to Connect
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
